Gravity Analytica

Talphera to Host Third Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, November 13, 2024

TLPH 11.06.2024

SERA-AI Powered Highlights

Date of Upcoming Event:2024-11-13

Name of Upcoming Event:Conference

Full Press Release SEC Filings Our TLPH Tweets

About Gravity Analytica

Recent Filings

SAN MATEO, Calif.,Nov. 6, 2024/PRNewswire/ --Talphera, Inc.(Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release third quarter 2024 financial results after market close onWednesday, November 13, 2024, then host a live webcast and conference call at4:30 p.m. Eastern Time/1:30 p.m.Pacific Standard to discuss the results and provide an update on the Company's business.

Webcast Information

The webcast can be accessedhereor by visiting the Investors section of the Company's website atwww.talphera.comand clicking on the webcast link posted within Investors/News & Events/Upcoming Events section. The webcast will include a slide presentation and a replay will be available on the Talphera website for 90 days following the event.

Conference Call Information

Investors who wish to participate in the conference call may do so by dialing 1-800-836-8184 for North American callers, or 1-646-357-8785 (toll applies) for international callers outside ofCanada. The conference ID is 89949.

AboutTalphera, Inc.

Talphera, Inc.is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera's lead product candidate, NiyadTM is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation status from theU.S. Food and Drug Administration(FDA). Talphera is also developing two pre-filled syringes in-licensed from its partner Aguettant: FedsyraTM, a pre-filled ephedrine syringe, and PFS-02, a pre-filled phenylephrine syringe.

This release is intended for investors only. For additional information about Talphera, please visitwww.talphera.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/talphera-to-host-third-quarter-2024-financial-results-and-corporate-update-call-and-webcast-on-wednesday-november-13-2024-302297952.html

SOURCETalphera, Inc.

Talphera, Raffi Asadorian, CFO, 650-216-3500, investors@talphera.com; LifeSci Advisors, Kevin Gardner, 617-283-2856, kgardner@lifesciadvisors.com; Chris Calabrese, 917-680-5608, ccalabrese@lifesciadvisors.com

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com